High-dose chemotherapy and multiple sclerosis

Daniel Harrison, Douglas Gladstone

Research output: Contribution to journalArticle

Abstract

Purpose of review: Immunomodulatory medications for multiple sclerosis provide only modest control of this potentially debilitating auto-immune disease of the central nervous system. The immunosuppression provided by high-dose chemotherapy has been studied to address treatment-refractory disease. In this review, we discuss the recent significant work in this field and its associated controversies. Recent findings: Conclusive evidence for the efficacy of high-dose chemotherapy with stem cell rescue is lacking given the lack of uniform patient populations and varying treatment protocols. Moreover, the significant toxicity associated with this procedure has dampened enthusiasm for its widespread use. High-dose chemotherapy without stem cell rescue has been trialed as a less toxic approach that eliminates the possibility of re-infusing autoreactive lymphocytes found in the stem cell product. Summary: Before high-dose chemotherapy with or without stem cell rescue can be adopted for clinical practice, both approaches require testing in randomized clinical trials. Both procedures have the possibility of decreasing disease activity but high-dose chemotherapy without stem cell rescue having a more favorable safety profile, may prove a more significant advance in the field of high-dose therapy for multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)221-226
Number of pages6
JournalCurrent Opinion in Oncology
Volume23
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Multiple Sclerosis
Stem Cells
Drug Therapy
Poisons
Immune System Diseases
Clinical Protocols
Immunosuppression
Central Nervous System
Randomized Controlled Trials
Lymphocytes
Safety
Therapeutics
Population

Keywords

  • autologous stem cell transplantation
  • high-dose cyclophosphamide
  • multiple sclerosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose chemotherapy and multiple sclerosis. / Harrison, Daniel; Gladstone, Douglas.

In: Current Opinion in Oncology, Vol. 23, No. 2, 03.2011, p. 221-226.

Research output: Contribution to journalArticle

Harrison, Daniel ; Gladstone, Douglas. / High-dose chemotherapy and multiple sclerosis. In: Current Opinion in Oncology. 2011 ; Vol. 23, No. 2. pp. 221-226.
@article{b686cc38cf424a81967b9bf409de462f,
title = "High-dose chemotherapy and multiple sclerosis",
abstract = "Purpose of review: Immunomodulatory medications for multiple sclerosis provide only modest control of this potentially debilitating auto-immune disease of the central nervous system. The immunosuppression provided by high-dose chemotherapy has been studied to address treatment-refractory disease. In this review, we discuss the recent significant work in this field and its associated controversies. Recent findings: Conclusive evidence for the efficacy of high-dose chemotherapy with stem cell rescue is lacking given the lack of uniform patient populations and varying treatment protocols. Moreover, the significant toxicity associated with this procedure has dampened enthusiasm for its widespread use. High-dose chemotherapy without stem cell rescue has been trialed as a less toxic approach that eliminates the possibility of re-infusing autoreactive lymphocytes found in the stem cell product. Summary: Before high-dose chemotherapy with or without stem cell rescue can be adopted for clinical practice, both approaches require testing in randomized clinical trials. Both procedures have the possibility of decreasing disease activity but high-dose chemotherapy without stem cell rescue having a more favorable safety profile, may prove a more significant advance in the field of high-dose therapy for multiple sclerosis.",
keywords = "autologous stem cell transplantation, high-dose cyclophosphamide, multiple sclerosis",
author = "Daniel Harrison and Douglas Gladstone",
year = "2011",
month = "3",
doi = "10.1097/CCO.0b013e328342c6b3",
language = "English (US)",
volume = "23",
pages = "221--226",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - High-dose chemotherapy and multiple sclerosis

AU - Harrison, Daniel

AU - Gladstone, Douglas

PY - 2011/3

Y1 - 2011/3

N2 - Purpose of review: Immunomodulatory medications for multiple sclerosis provide only modest control of this potentially debilitating auto-immune disease of the central nervous system. The immunosuppression provided by high-dose chemotherapy has been studied to address treatment-refractory disease. In this review, we discuss the recent significant work in this field and its associated controversies. Recent findings: Conclusive evidence for the efficacy of high-dose chemotherapy with stem cell rescue is lacking given the lack of uniform patient populations and varying treatment protocols. Moreover, the significant toxicity associated with this procedure has dampened enthusiasm for its widespread use. High-dose chemotherapy without stem cell rescue has been trialed as a less toxic approach that eliminates the possibility of re-infusing autoreactive lymphocytes found in the stem cell product. Summary: Before high-dose chemotherapy with or without stem cell rescue can be adopted for clinical practice, both approaches require testing in randomized clinical trials. Both procedures have the possibility of decreasing disease activity but high-dose chemotherapy without stem cell rescue having a more favorable safety profile, may prove a more significant advance in the field of high-dose therapy for multiple sclerosis.

AB - Purpose of review: Immunomodulatory medications for multiple sclerosis provide only modest control of this potentially debilitating auto-immune disease of the central nervous system. The immunosuppression provided by high-dose chemotherapy has been studied to address treatment-refractory disease. In this review, we discuss the recent significant work in this field and its associated controversies. Recent findings: Conclusive evidence for the efficacy of high-dose chemotherapy with stem cell rescue is lacking given the lack of uniform patient populations and varying treatment protocols. Moreover, the significant toxicity associated with this procedure has dampened enthusiasm for its widespread use. High-dose chemotherapy without stem cell rescue has been trialed as a less toxic approach that eliminates the possibility of re-infusing autoreactive lymphocytes found in the stem cell product. Summary: Before high-dose chemotherapy with or without stem cell rescue can be adopted for clinical practice, both approaches require testing in randomized clinical trials. Both procedures have the possibility of decreasing disease activity but high-dose chemotherapy without stem cell rescue having a more favorable safety profile, may prove a more significant advance in the field of high-dose therapy for multiple sclerosis.

KW - autologous stem cell transplantation

KW - high-dose cyclophosphamide

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=79952007067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952007067&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328342c6b3

DO - 10.1097/CCO.0b013e328342c6b3

M3 - Article

C2 - 21169833

AN - SCOPUS:79952007067

VL - 23

SP - 221

EP - 226

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -